Hồ sơ nguồn sơ cấp
Mang tính quyết địnhĐã nộp đơn
Beam Therapeutics dự kiến nộp đơn BLA cho risto-cel sớm nhất vào cuối năm 2026
The 8-K confirms that the company expects to submit a U.S. BLA for risto-cel in sickle cell disease as early as December 2026, supported by a new $500 million non-dilutive credit facility with Sixth Street that extends cash runway into mid-2029 and funds the anticipated commercial launch.
Thông tin chính
- Nộp lúc
- 12:05 24 thg 2, 2026
- Sự kiện
- Đã nộp đơn
- Chiều hướng
- Tích cực
- Công ty
BEAMBeam Therapeutics- Tài sản
- risto-cel
- Nguồn
- SEC 8-K
- Độ tin cậy
- Có nguồn
- thời gian tiền mặt
- giữa năm 2029
- số tiền rút tối thiểu
- 200 triệu đô la
- cơ sở tiền mặt
- 500 triệu đô la
Trích đoạn nguồn
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Ca